Maryland Heights, MO, February 17, 2017 --(PR.com
)-- The global dyslipidemia drugs market decline to reach nearly USD 9.5 Billion in 2020, at a CAGR of 10.3% from 2016 to 2020, due to patent expirations and absence of new drugs worldwide.
Browse Dyslipidemia Drugs Market by Drug Class (Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacin, Statins, and Other Drugs – Combination Drugs and Cholesterol Absorption Inhibitors) 2016-2020 at https://www.ihealthcareanalyst.com/report/dyslipidemia-drugs-market/
Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. Dyslipidemia has emerged as a major health concern across the world. The major effects of the lipid lowering drugs include lowering of serum low density lipoprotein (LDL) cholesterol levels which are believed to predispose to atherosclerosis and its complications, acute myocardial infarction, cerebrovascular ischemic stroke and peripheral vascular disease. There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine).
The global dyslipidemia drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug class (bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacin, statins, and other drugs such as combination drugs and cholesterol absorption inhibitors), and forecasts growth trends (CAGR% - 2016 to 2020). The global dyslipidemia drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global dyslipidemia drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global dyslipidemia drugs market and included in this report are Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc.
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043